Skip to Content
Merck
All Photos(1)

Key Documents

B-902

Supelco

Buprenorphine solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C29H41NO4
CAS Number:
Molecular Weight:
467.64
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

concentration

100 μg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56

InChI

1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1

InChI key

RMRJXGBAOAMLHD-IHFGGWKQSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Sold under the trade names Buprenex®, Subutex® and Suboxone®, buprenorphine is an opiate drug used to treat opioid addiction and moderate acute pain. This Certified Spiking Solution® standard is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or pharmaceutical research.

Application


  • Research on Addiction and Implementation Challenges: Buprenorphine solutions have been crucial in studies exploring how systemic barriers affect the implementation of addiction treatments during concurrent public health crises, offering insights valuable for policy and practice adjustments in healthcare systems (Sharp et al., 2023).

  • Evaluating Patient-Important Measures in Opioid Use Disorder Treatments: Buprenorphine is used extensively to evaluate patient-important outcomes in medication-assisted treatment programs for opioid use disorders, aiding in the assessment of long-term recovery metrics and treatment efficacy (Reed et al., 2023).

  • Web-Based Substance Use Epidemiology Research: Buprenorphine research solutions are instrumental in developing web-based ontologies for tracking and analyzing drug abuse trends, providing a foundational tool for public health surveillance and policy-making in substance abuse epidemiology (Lokala et al., 2022).

  • Clinical Studies in Veterinary Medicine: Buprenorphine solutions are employed in veterinary medicine to assess the efficacy of transdermal applications for managing postoperative pain in animals, demonstrating its versatility and effectiveness across different biological systems (Clark et al., 2022).

  • Pain Management in Geriatric Orthopedics: The use of transdermal buprenorphine for managing pain following femur fractures in elderly patients highlights its critical role in improving postoperative care and enhancing recovery outcomes in geriatric orthopedics (Davies et al., 2022).

Legal Information

Buprenex is a registered trademark of Reckitt & Colman (Overseas) Ltd
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited

related product

Product No.
Description
Pricing

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Y Ledoux
Journal de pharmacie de Belgique, (3)(3), 30-39 (2013-05-24)
The Substitution Treatment National Registry provided from mid 2006 till mid 2009 an exhaustive documentation on all patients being prescribed methadone or buprenorphine in Belgium. This endeavour was possible through cooperation of all community pharmacies and their representative organizations was
Johan Menten et al.
Cancer investigation, 31(6), 412-420 (2013-06-14)
Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100
Karen L Cropsey et al.
Journal of addiction medicine, 7(3), 210-215 (2013-04-24)
This project sought to demonstrate the feasibility and acceptability of providing on-site buprenorphine treatment to individuals under community corrections supervision. Seventeen women and 13 men were enrolled on-site over a 2-week period at a community corrections location. Study participants received
E J Love et al.
The Veterinary record, 172(24), 635-635 (2013-06-06)
Buprenorphine has recently obtained UK Marketing Authorisation for horses. The analgesic effects are long lasting, and have considerable potential for postoperative pain relief. This observer blinded, randomised study aimed to evaluate postsurgical analgesia in ponies premedicated with buprenorphine prior to
P M J Clement et al.
Acta clinica Belgica, 68(2), 87-91 (2013-08-24)
Despite guidelines and recommendations, a large proportion of patients with cancer still have inadequate pain control. Transdermal opioid administration can overcome problems such as swallowing and compliance, because only one application every three days is needed. Transdermal buprenorphine was documented

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service